SCENTMATIC
SCENTMATIC Inc (CEO: Toshiharu Kurisu, Head office: Tokyo, Japan), which proposes new customer experiences through the digitization of fragrance, announced that their AI service that verbalizes fragrance KAORIUM has been selected as “Retracing innovation and ideas that defined the lifestyle trends of 2023” by STIRworld.com, a leading global digital magazine in the fields of design, architecture, and arts.
* KAORIUM is a registered trademark of SCENTMATIC Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328876250/en/
What's KAORIUM? Read scents, smell words; A journey of fragrance discovery that ignites the olfactory imagination. Finding a perfume is a challenge. Fragrances are hard to grasp, and expressing our preferences can be tough. KAORIUM by SCENTMATIC is an entirely novel approach to fragrance exploration that decodes the enigmatic world of scents and helps people discover new fragrances intuitively through language. Harnessing state-of-the-art technology, our mission is to deliver olfactory moments of delight. When a scent is placed on the coaster, the impression of the scent is visualized in words. By expressing sensory perceptions through language, scents that were once difficult to discern become more clearly perceivable. (Graphic: Business Wire)
STIRworld.com Article page (Published 17 December 2023)
“Retracing innovation and ideas that defined the lifestyle trends of 2023”
https://www.stirworld.com/see-features-retracing-innovation-and-ideas-that-defined-the-lifestyle-trends-of-2023
The article introduces KAORIUM as one of the lifestyle trends that will have a major impact on the global design structure in 2023. The article describes KAORIUM’s process of scent, language, and artificial intelligence uniting to refine the user's scent preferences as “an immersive experience”. KAORIUM was highly evaluated as a lifestyle trend for 2023, defining a new retail experience that cannot be found in traditional perfume selling counters.
About KAORIUM
https://www.youtube.com/embed/0fpDr3zgjeM?feature=oembed
The article was also featured on the Instagram account of STIRworld.com.
STIRworld.com Instagram reel video (Posted on 20 December 2023)
https://www.instagram.com/reel/C1CqKsNywAD/?igsh=cXJxczUzanhxa2to
KAORIUM was in the spotlight when we exhibited this AI system that mutually converts scents and words at the London Design Festival 2023, one of the world's leading design events, held in London, UK, for eight days from 16 to 24 September 2023.
STIRworld.com Article page (Published on 19 September 2023)
https://www.stirworld.com/see-lifestyle-scentmatics-kaorium-at-ldf-2023-explores-language-and-emotion-in-fragrance-selection
In the interview with STIR, Kurisu, Managing Director of SCENTMATIC, introduced the innovations brought by KAORIUM to the Japanese retail industry, as well as its future potential and social impact.
GET IN TOUCH
https://scentmatic.co.jp/contact-en
[SCENTMATIC, Inc.]
SCENTMATIC was established in 2019 as a co-creation fragrance business design group that can add "emotional experience value" to everything using an AI system that verbalizes fragrance. Focusing on the most unknown area of the five senses “smell”, we have developed KAORIUM, an AI tool that verbalizes fragrance. KAORIUM is expected to help businesses to utilize fragrance in a variety of ways. SCENTMATIC is working on the 'digitalization of the sense of smell'. It will revolutionize business in all industries by evolving people's senses through the 'experience of smell' using fragrance and words.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328876250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom